N2OFF files MitoCareX audited financials; target had $886K net loss, going concern doubt in 2024

Nexentis Technologies Inc.

MitoCareX net loss for 2024 was $886K, accumulated deficit $1,760K; cash used in operations $797K.
Auditor notes substantial doubt about MitoCareX's ability to continue as a going concern.
MitoCareX had short-term loan of $250K from N2OFF at 3% due Dec 2024; second $250K loan in Mar 2025.
Unaudited pro forma combined financials filed for six months ended Jun 30, 2025 and year ended Dec 31, 2024.
Updated business description and risk factors filed to supplement prior disclosures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.